Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMY)
Filing Type: Form 8-K (Current Report)
Date of Report: February 6, 2025
Reporting Period: Fourth Quarter and Full Year 2024
This filing serves as a notification that the Company issued an Earnings Press Release and a presentation regarding its financial results for the fourth quarter and full year of 2024. The detailed financial data is contained in the exhibits (Exhibit 99.1 and 99.2) incorporated by reference, rather than in the body of this 8-K.
Key Financial Metrics
The text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are disclosed in the Earnings Press Release (Exhibit 99.1) and the Bristol Myers Presentation (Exhibit 99.2) referenced in the filing.
Material Changes
The filing does not detail specific material changes versus prior periods. It indicates that the Company has announced results for Q4 and full-year 2024, implying a comparison to prior periods is available in the referenced exhibits.
Guidance, Outlook, and Management Commentary
- Disclosure Method: Management commentary, guidance, and outlook are provided in the Earnings Press Release and the accompanying presentation materials.
- Non-GAAP Measures: The referenced materials include non-GAAP financial information. Reconciliations to GAAP measures are available in the Earnings Press Release.
- Availability: The presentation was posted on the Company's website for viewing during the conference call. The Company reserves the right to discontinue availability of the presentation at any time.
- Legal Status: Information in Item 7.01 (Regulation FD Disclosure) is not deemed "filed" under the Exchange Act and is not subject to Section 18 liabilities, nor is it incorporated by reference into future filings unless specifically stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings Press Release) for specific Q4 and full-year 2024 revenue, net income, and EPS figures.
- Examine Exhibit 99.2 (Presentation Materials) for management's strategic outlook and operational initiatives.
- Verify the reconciliation between non-GAAP and GAAP financial measures provided in the press release.
- Confirm the status of the 1.000% Notes due 2025 listed in the securities section, given the filing date is February 2025.
- Note that the presentation materials may be removed from the website at any time; investors should download or archive them if needed for long-term reference.